Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review
Biomolecules · 19.10.2023 · 13 (10) · 1543
DOI: 10.3390/biom13101543 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 19.10.2023. Verfasst von Shingo Nakahata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima 890-854…. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, Lymphoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, the Kobayashi Foundation for Cancer Research.
Abstract (Originalsprache)
Human T-cell leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL). HTLV-1 carriers have a lifelong asymptomatic balance between infected cells and host antiviral immunity; however, 5–10% of carriers lose this balance and develop ATL. Coinfection with Strongyloides promotes ATL development, suggesting that the immunological status of infected individuals is a determinant of HTLV-1 pathogenicity. As CD4+ T cells play a central role in host immunity, the deregulation of their function and differentiation via HTLV-1 promotes the immune evasion of infected T cells. During ATL development, the accumulation of genetic and epigenetic alterations in key host immunity-related genes further disturbs the immunological balance. Various approaches are available for treating these abnormalities; however, hematopoietic stem cell transplantation is currently the only treatment with the potential to cure ATL. The patient’s immune state may contribute to the treatment outcome. Additionally, the activity of the anti-CC chemokine receptor 4 antibody, mogamulizumab, depends on immune function, including antibody-dependent cytotoxicity. In this comprehensive review, we summarize the immunopathogenesis of HTLV-1 infection in ATL and discuss the clinical findings that should be considered when developing treatment strategies for ATL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima 890-8544, Japan.
- Division of Genomics and Transcriptomics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-8556, Japan.
ORCID-Profile: Daniel Enriquez-Vera, Yorifumi Satou
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- the Kobayashi Foundation for Cancer Research
- Kumamoto University
Zitieren
APA
Nakahata, S., Enriquez-Vera, D., Jahan, M. I., Sugata, K., & Satou, Y. (2023). Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review. Biomolecules, 13(10), 1543. https://doi.org/10.3390/biom13101543
Vancouver
Nakahata S, Enriquez-Vera D, Jahan MI, Sugata K, Satou Y. Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review. Biomolecules. 2023;13(10):1543. doi:10.3390/biom13101543
BibTeX
@article{Nakahata2023,
author = {Nakahata, Shingo and Enriquez-Vera, Daniel and Jahan, M Ishrat and Sugata, Kenji and Satou, Yorifumi},
title = {Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {10},
pages = {1543},
doi = {10.3390/biom13101543}
}
EUVIMED